Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients

Most patients being diagnosed with primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) are 60 years or older. Elderly patients with PCNSL have a poor prognosis and there is a great medical need to improve outcome for this vulnerable population. In Germany and many international centres, there are currently two widely used strategies to treat elderly PCNSL patients who are eligible for high-dose methotrexate (HD-MTX) treatment, which have not yet been compared head-to-head. The R-MP regimen has been established by the Cooperative PCNSL Study Group as a "conventional" imm

Trial Details

NCT ID
NCT06830421
Phase
PHASE3
Sponsor
University Hospital Freiburg
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • R-MP and Procarbazine maintenance
  • R-MTX/AraC (MARTA) induction followed by consolidating HCT-ASCT
Locations (sample)
  • Freiburg im Breisgau, Baden-Wurttemberg, Germany|47.9959,7.85222
  • Stuttgart, Baden-Wurttemberg, Germany|48.78232,9.17702
  • Aachen, Germany|50.77664,6.08342
  • Augsburg, Germany|48.37154,10.89851
  • Berlin, Germany|52.52437,13.41053

Key Eligibility Criteria

  • Immunocompetent patients with newly-diagnosed primary DLBCL of the central nervous system.
  • Age \> 70 years or age 65-70 years if not eligible for more intensive treatment (e.g. OptiMATe trial).
  • Histologically or cytologically assessed diagnosis of B-cell lymphoma by local pathologist.
  • Diagnostic sample obtained by stereotactic or surgical biopsy, cerebrospinal fluid (CSF) cytology examination or vitrectomy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →